BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™
Rhea-AI Summary
BriaCell Therapeutics (Nasdaq: BCTX) announced a manufacturing arrangement with FUJIFILM Biotechnologies California, a cell-therapy CDMO, to provide capacity for the remainder of BriaCell’s pivotal Phase 3 study and potential future commercial supply of Bria-IMT, an off-the-shelf allogeneic cell therapy for metastatic breast cancer.
Positive
- Manufacturing capacity secured for remainder of pivotal Phase 3 Bria-IMT study
- FUJIFILM Biotechnologies adds experienced CDMO partner for Bria-IMT cell therapy
- Arrangement includes potential future commercial supply scalability for Bria-IMT
Negative
- None.
News Market Reaction – BCTX
In the Jul 15 session, BCTX gained 6.49%, reflecting a notable positive market reaction. Argus tracked a peak move of +3.9% during that session. Argus tracked a trough of -5.2% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 07 | commercial planning news | Positive | -0.3% | Engaged consultants for Bria-IMT commercial strategy and market access planning. |
| Jun 25 | device partnership | Positive | -2.0% | Signed MoU with Uneedle for scalable microneedle administration of Bria-IMT. |
| Jun 02 | equity offering closing | Negative | +1.2% | Closed best-efforts equity offering raising gross proceeds for corporate purposes. |
| Jun 02 | ASCO clinical data | Positive | -9.1% | Presented positive Phase 2 and Phase 3 regimen data in metastatic breast cancer at ASCO. |
| May 31 | equity offering pricing | Negative | -9.1% | Priced best-efforts offering of common shares for expected gross cash proceeds. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent BriaCell headlines, including clinical data and partnerships, have more often coincided with downside moves than with price gains.
Key Terms
pivotal phase 3 medical
immune checkpoint inhibitor medical
allogenic cell therapy medical
contract development and manufacturing organization technical
metastatic breast cancer medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Arrangement with FUJIFILM Biotechnologies California provides manufacturing capacity for the remainder of BriaCell’s pivotal Phase 3 study and commercial scalability potential
- Bria-IMT is currently being evaluated in Bria-Cell’s ongoing pivotal Phase 3 study in metastatic breast cancer
PHILADELPHIA and VANCOUVER, British Columbia, July 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces a manufacturing arrangement with FUJIFILM Biotechnologies California, a leading contract development and manufacturing organization (CDMO) specializing in cell therapies, to support the ongoing pivotal Phase 3 clinical development and potential future commercial supply of BriaCell’s lead clinical candidate, Bria-IMT, an off-the-shelf allogenic cell therapy.
Bria-IMT is currently being evaluated in BriaCell’s pivotal Phase 3 study of Bria-IMT in combination with an immune checkpoint inhibitor in advanced metastatic breast cancer (ClinicalTrials.gov identifier: NCT06072612).
“Securing manufacturing capacity with Fujifilm, a global leader in cell therapy manufacturing, represents a key milestone in our Bria-IMT development and potential commercialization strategy as we work toward our goal of bringing this novel immunotherapy candidate to patients with metastatic breast cancer,” said William V. Williams, MD, President and Chief Executive Officer of BriaCell.
About BriaCell Therapeutics Corp.
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.
About FUJIFILM Biotechnologies California
FUJIFILM Biotechnologies California, a subsidiary of FUJIFILM Corporation, specializes in developing and manufacturing cell-based therapeutics. Located in Thousand Oaks, California, the company operates a state-of-the-art cell therapy manufacturing facility featuring cGMP production suites, quality control and development laboratories, and product storage and distribution capabilities. These facilities support both autologous and allogeneic cell therapy manufacturing while meeting global regulatory standards for advanced therapies and medicinal products. With its highly skilled and experienced workforce and regulatory agency approved manufacturing capabilities, FUJIFILM Biotechnologies California is shaping the future of medicine through the advanced production of cell therapies. The company leverages the global network and end-to-end CDMO capabilities of the Fujifilm Life Sciences Group to provide solutions that support complex cell therapy development and manufacturing.
About FUJIFILM
FUJIFILM Americas is the regional headquarters for the Americas. It is comprised of 20 group companies across North and Latin America that are engaged in the research, development, manufacture, sale and service of Fujifilm products and services. The company’s portfolio represents a broad spectrum of industries including medical and life sciences, electronic materials, chemical, graphic arts, information systems, industrial products, broadcast, data storage, and photography. For more information, please visit: https://www.fujifilm.com/us/en/about/region.
FUJIFILM Holdings Corporation, headquartered in Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver innovative products and services across the globe through the four key business segments of healthcare, electronics, business innovation, and imaging with over 70,000 employees. Guided and united by our Group Purpose of “giving our world more smiles,” we address social challenges and create a positive impact on society through our products, services, and business operations. Under its medium-term management plan, VISION2030, which ends in FY2030, we aspire to continue our evolution into a company that creates value and smiles for various stakeholders as a collection of global leading businesses and achieve a global revenue of 4 trillion
Safe Harbor
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about the manufacturing arrangement with FUJIFILM Biotechnologies California, the availability of manufacturing capacity to support the remainder of BriaCell’s ongoing pivotal Phase 3 study, the potential for future commercial-scale manufacturing of Bria-IMT, the continued development and commercialization of Bria-IMT, and the evaluation of Bria-IMT in BriaCell’s ongoing pivotal Phase 3 study in advanced metastatic breast cancer, are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, under the heading “Risk Factors” in the Company’s most recent Annual Information Form, and under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company’s profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Investor Relations Contact:
investors@briacell.com
